{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:49:10Z","timestamp":1783061350668,"version":"3.54.6"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jaut.2025.103390","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T20:48:32Z","timestamp":1741034912000},"page":"103390","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Autoantibodies against \u03b1-synuclein inhibit its aggregation and cytotoxicity"],"prefix":"10.1016","volume":"152","author":[{"given":"Carmen","family":"Noelker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annekathrin","family":"Sturn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"Neff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luminita-Cornelia","family":"Andrei-Selmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Rau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Geyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alexander","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2044-6299","authenticated-orcid":false,"given":"Richard","family":"Dodel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2025.103390_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/nan.12298","article-title":"Review: sporadic Parkinson's disease: development and distribution of alpha-synuclein pathology","volume":"42","author":"Del Tredici","year":"2016","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.jaut.2025.103390_bib2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2025.103390_bib3","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s004010050918","article-title":"Accumulation of alpha-synuclein\/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy","volume":"96","author":"Wakabayashi","year":"1998","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.jaut.2025.103390_bib4","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson's disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.jaut.2025.103390_bib5","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1090278","article-title":"alpha-Synuclein locus triplication causes Parkinson's disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jaut.2025.103390_bib6","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ana.10795","article-title":"The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia","volume":"55","author":"Zarranz","year":"2004","journal-title":"Ann. Neurol."},{"issue":"Suppl 1","key":"10.1016\/j.jaut.2025.103390_bib7","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.parkreldis.2015.08.015","article-title":"Phenotypic spectrum of alpha-synuclein mutations: new insights from patients and cellular models","volume":"22","author":"Petrucci","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.jaut.2025.103390_bib8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0006-8993(00)02215-0","article-title":"Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells","volume":"866","author":"Zhou","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.jaut.2025.103390_bib9","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1126\/science.287.5456.1265","article-title":"Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders","volume":"287","author":"Masliah","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.jaut.2025.103390_bib10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0925-4439(00)00036-3","article-title":"Properties of NACP\/alpha-synuclein and its role in Alzheimer's disease","volume":"1502","author":"Iwai","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jaut.2025.103390_bib11","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1074\/jbc.M008919200","article-title":"A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly","volume":"276","author":"Giasson","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jaut.2025.103390_bib12","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nature15368","article-title":"Structure of the toxic core of alpha-synuclein from invisible crystals","volume":"525","author":"Rodriguez","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2025.103390_bib13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0006-8993(01)02575-6","article-title":"Multiple ligand interaction of alpha-synuclein produced various forms of protein aggregates in the presence of Abeta25-35, copper, and eosin","volume":"908","author":"Kim","year":"2001","journal-title":"Brain Res."},{"key":"10.1016\/j.jaut.2025.103390_bib14","doi-asserted-by":"crossref","first-page":"28512","DOI":"10.1074\/jbc.M111971200","article-title":"Distinct roles of the N-terminal-binding domain and the C-terminal-solubilizing domain of alpha-synuclein, a molecular chaperone","volume":"277","author":"Park","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jaut.2025.103390_bib15","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41467-018-03111-4","article-title":"C-terminal calcium binding of alpha-synuclein modulates synaptic vesicle interaction","volume":"9","author":"Lautenschlager","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jaut.2025.103390_bib16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0896-6273(03)00684-6","article-title":"Caught in the act: alpha-synuclein is the culprit in Parkinson's disease","volume":"40","author":"Eriksen","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.jaut.2025.103390_bib17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1006\/mcne.2000.0923","article-title":"Reduced neuritic outgrowth and cell adhesion in neuronal cells transfected with human alpha-synuclein","volume":"17","author":"Takenouchi","year":"2001","journal-title":"Molecular and cellular neurosciences"},{"key":"10.1016\/j.jaut.2025.103390_bib18","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1750-3639.1999.tb00552.x","article-title":"Alpha-synuclein in Lewy body disease and Alzheimer's disease","volume":"9","author":"Hashimoto","year":"1999","journal-title":"Brain Pathol."},{"key":"10.1016\/j.jaut.2025.103390_bib19","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1073\/pnas.1100976108","article-title":"In vivo demonstration that alpha-synuclein oligomers are toxic","volume":"108","author":"Winner","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jaut.2025.103390_bib20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2025.103390_bib21","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s13311-022-01288-7","article-title":"Alpha-synuclein immunization strategies for synucleinopathies in clinical studies: a biological perspective","volume":"19","author":"Knecht","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jaut.2025.103390_bib22","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.neuron.2005.05.010","article-title":"Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease","volume":"46","author":"Masliah","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.jaut.2025.103390_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/biom12020168","article-title":"Passive immunization in alpha-synuclein preclinical animal models","volume":"12","author":"Folke","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.jaut.2025.103390_bib24","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.nbd.2018.11.024","article-title":"Naturally occurring autoantibodies against alpha-synuclein rescues memory and motor deficits and attenuates alpha-synuclein pathology in mouse model of Parkinson's disease","volume":"124","author":"Huang","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jaut.2025.103390_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/nan.12860","article-title":"Novel naturally occurring autoantibodies attenuate alpha-synuclein pathology in a mouse model of Parkinson's disease","volume":"49","author":"Li","year":"2023","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.jaut.2025.103390_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241311022","article-title":"Are therapies that target alpha-synuclein effective at halting Parkinson's disease progression? A systematic review","volume":"24","author":"Rodger","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jaut.2025.103390_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108870","article-title":"Targeting alpha-synuclein via the immune system in Parkinson's disease: current vaccine therapies","volume":"202","author":"Fleming","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jaut.2025.103390_bib28","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s13311-022-01288-7","article-title":"Alpha-synuclein immunization strategies for synucleinopathies in clinical studies: a biological perspective","volume":"19","author":"Knecht","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jaut.2025.103390_bib29","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2203395","article-title":"Trial of cinpanemab in early Parkinson's disease","volume":"387","author":"Lang","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2025.103390_bib30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of prasinezumab in early-stage Parkinson's disease","volume":"387","author":"Pagano","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2025.103390_bib31","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.3233\/JPD-229008","article-title":"This is not the end for immunotherapy in Parkinson's disease - a perspective from early drug development scientists","volume":"12","author":"Brundin","year":"2022","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.jaut.2025.103390_bib32","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1471-4159.2006.04365.x","article-title":"Autoantibodies to alpha-synuclein in inherited Parkinson's disease","volume":"101","author":"Papachroni","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jaut.2025.103390_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/biom12030469","article-title":"Alpha-synuclein-specific naturally occurring antibodies inhibit aggregation in vitro and in vivo","volume":"12","author":"Braczynski","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.jaut.2025.103390_bib34","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00401-019-01974-5","article-title":"Naturally occurring antibodies isolated from PD patients inhibit synuclein seeding in vitro and recognize Lewy pathology","volume":"137","author":"Li","year":"2019","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.jaut.2025.103390_bib35","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.neulet.2019.04.004","article-title":"Effect of naturally occurring alpha-synuclein-antibodies on toxic alpha-synuclein-fragments","volume":"704","author":"Rabenstein","year":"2019","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jaut.2025.103390_bib36","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1016\/j.jchromb.2010.06.039","article-title":"Reducing sample complexity of polyclonal human autoantibodies by chromatofocusing","volume":"878","author":"Hagemann","year":"2010","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.jaut.2025.103390_bib37","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1074\/mcp.M500108-MCP200","article-title":"Novel Src homology 3 domain-binding motifs identified from proteomic screen of a Pro-rich region","volume":"4","author":"Jia","year":"2005","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.jaut.2025.103390_bib38","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0002-9440(10)63072-6","article-title":"Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model","volume":"159","author":"Kahle","year":"2001","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jaut.2025.103390_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003394","article-title":"Inhibition of alpha-synuclein fibrillization by dopamine is mediated by interactions with five C-terminal residues and with E83 in the NAC region","volume":"3","author":"Herrera","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2025.103390_bib40","doi-asserted-by":"crossref","first-page":"27638","DOI":"10.1074\/jbc.M113.463273","article-title":"Synthetic dimeric Abeta(28-40) mimics the complex epitope of human anti-Abeta autoantibodies against toxic Abeta oligomers","volume":"288","author":"Roeder","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jaut.2025.103390_bib41","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1046\/j.1432-1327.2000.01219.x","article-title":"Toxicity of non-abeta component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of beta-sheet structure and fibrils","volume":"267","author":"Bodles","year":"2000","journal-title":"Eur. J. Biochem.\/FEBS"},{"key":"10.1016\/j.jaut.2025.103390_bib42","doi-asserted-by":"crossref","first-page":"11970","DOI":"10.1074\/jbc.M109541200","article-title":"Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins","volume":"277","author":"Uversky","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jaut.2025.103390_bib43","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0896-6273(01)00462-7","article-title":"beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor","volume":"32","author":"Hashimoto","year":"2001","journal-title":"Neuron"},{"key":"10.1016\/j.jaut.2025.103390_bib44","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1073\/pnas.97.9.4897","article-title":"Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation","volume":"97","author":"Serpell","year":"2000","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.jaut.2025.103390_bib45","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","article-title":"alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies","volume":"95","author":"Spillantini","year":"1998","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.jaut.2025.103390_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202954","article-title":"Extending the functional characteristics of naturally occurring autoantibodies against beta-Amyloid, Prion Protein and alpha-Synuclein","volume":"13","author":"Albus","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2025.103390_bib47","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/3311","article-title":"Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease","volume":"4","author":"Conway","year":"1998","journal-title":"Nature medicine"},{"key":"10.1016\/j.jaut.2025.103390_bib48","first-page":"1169","article-title":"Abnormal distribution of the non-Abeta component of Alzheimer's disease amyloid precursor\/alpha-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment","volume":"78","author":"Takeda","year":"1998","journal-title":"Laboratory investigation; a journal of technical methods and pathology"},{"key":"10.1016\/j.jaut.2025.103390_bib49","doi-asserted-by":"crossref","first-page":"11282","DOI":"10.1073\/pnas.90.23.11282","article-title":"Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease","volume":"90","author":"Ueda","year":"1993","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.jaut.2025.103390_bib50","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1523\/JNEUROSCI.0285-07.2007","article-title":"Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo","volume":"27","author":"Periquet","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jaut.2025.103390_bib51","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ana.10253","article-title":"Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease","volume":"52","author":"Dodel","year":"2002","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jaut.2025.103390_bib52","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/brain\/awg191","article-title":"Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity","volume":"126","author":"Du","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.jaut.2025.103390_bib53","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.molbrainres.2003.11.011","article-title":"A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease","volume":"121","author":"Murphy","year":"2004","journal-title":"Mol. Brain Res."},{"key":"10.1016\/j.jaut.2025.103390_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcn.2022.103746","article-title":"The relevance of synuclein autoantibodies as a biomarker for Parkinson's disease","volume":"121","author":"Garg","year":"2022","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.jaut.2025.103390_bib55","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3389\/fneur.2018.00815","article-title":"A systematic review and meta-analysis of alpha synuclein auto-antibodies in Parkinson's disease","volume":"9","author":"Scott","year":"2018","journal-title":"Front. Neurol."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841125000356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841125000356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T04:24:09Z","timestamp":1762316649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841125000356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":55,"alternative-id":["S0896841125000356"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103390","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoantibodies against \u03b1-synuclein inhibit its aggregation and cytotoxicity","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103390","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103390"}}